This analysis showed that the RIPK2 had a higher expression in gastric, breast, esophageal, colorectal, head and neck, liver, kidney, as well as pancreatic cancers, myeloma and sarcoma, compared to that in the respective normal tissues (Figure 1A). Here, RIPK2 is linked to plasma cell myeloma.